Bladder cancer combo trial pulled before it began
NCT ID NCT07551544
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if adding ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade type of bladder cancer that hasn't spread into the muscle. It was designed for adults with papillary tumors who had not received BCG before or had limited exposure. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- Engineered TB bacteria could offer new hope for bladder cancer patients
- Bladder cancer patients get new hope from virus therapy
- New biologic combo aims to spare bladders in cancer fight
- New hope for bladder cancer patients: experimental drug combo aims to beat chemo
- New bladder cancer drug shows early promise in small trial